他汀类药物抗肿瘤作用的研究进展

摘要/Abstract

摘要：

3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂，通常称为他汀类药物，由于其在心血管疾病防治方面证实的有效性和安全性，是目前临床上最广泛使用的降脂药之一。研究发现，他汀类药物具有降低胆固醇外的其他作用。在其抗肿瘤作用的研究方面发现，他汀类药物可以影响细胞生长、凋亡和炎症反应等，并且可以降低肿瘤风险、提高肿瘤病人的生存率。这些研究目前存在一些争议，还需要进一步的进行临床前和临床研究的验证。本文综述了近年来他汀类药物在肿瘤中的临床前及临床研究数据，并讨论了当前的研究状态和他汀类药物作为未来肿瘤化疗防治药物的潜力。

关键词: 他汀类药物, 抗肿瘤作用, 细胞生长, 炎症反应, 凋亡

Abstract:

The 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are the most prescribed lipid-lowering drugs in clinic on account of their demonstrated safety and efficacy in prevention and treatment of cardiovascular diseases. Beyond their potent inhibition effects in cholesterol biosynthesis, statins appear to have pleiotropic effects in cancer. In the respect of anti-tumor effect, statins could modulate the cell growth, apoptosis, and inflammation, as well as reduce cancer risk and improve survival of patients. There are some scientific controversies in current studies, and more pre-clinical and clinical verification studies are needed. Herein we review the pre-clinical and clinical data relevant to statins and their anti-tumor effects in recent years, and discuss the current status and the potential of statins as chemopreventive drugs in future.

Key words: statins, anti-tumor effect, cell growth, inflammatory response, apoptosis

中图分类号:

R968

邓俊丽，张蕊，唐洁，王果，朱院山. 他汀类药物抗肿瘤作用的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(1): 92-99.

DENG Junli, ZHANG Rui, TANG Jie, WANG Guo, ZHU Yuanshan. Research progress on the anti-tumor effects of statins[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 92-99.

参考文献

［1］Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia［J］. N Engl J Med,1988,319(1):24-33.
［2］Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins［J］. Lancet,2005,366(9493):1267-1278.
［3］Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer［J］. Pharmacol Rev,2012,64(1):102-146.
［4］Furuya Y, Sekine Y, Kato H,et al. Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins［J］. Prostate Int, 2016, 4(2):56-60.
［5］Kimbung S, Lettiero B, Feldt M,et al. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer［J］. Oncotarget, 2016 Jul 21.doi: 10.18632/oncotarget.10746. ［Epub ahead of print］
［6］Matusewicz L, Meissner J, Toporkiewicz M, et al.The effect of statins on cancer cells--review［J］. Tumour Biol,2015,36(7):4889-4904.
［7］Stryjkowska-Góra A, Karczmarek-Borowska B, Góra T,et al. Statins and cancers［J］. Contemp Oncol (Pozn), 2015,19(3):167-175.
［8］Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011,47(6):819-830.
［9］Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer［J］. Pharmacol Rev,2012,64(1):102-146.
［10］Duncan RE, El-Sohemy A, Archer MC.Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity［J］. J Biol Chem,2004,279(32):33079-33084.
［11］Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins［J］. Oncogene,2012,31(48):4967-4978.
［12］Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase［J］. Proc Natl Acad Sci USA. 1999,96(14):7797-7802.
［13］Tu YS, Kang XL, Zhou JG, et al. Involvement of Chk1-Cdc25A-cyclin A/CDk2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells［J］. Eur J Pharmacol,2011,670(2/3):356-364.
［14］Spampanato C, De Maria S, Sarnataro M, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and downregulation of BCL-2 gene expression［J］. Int J Oncol,2012,40(4):935-941.
［15］Herrero-Martin G, Lopez-Rivas A. Statins activate a mitochondriaoperated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins［J］. FEBS Lett,2008,582(17):2589-2594.
［16］Buranrat B, Senggunprai L, Prawan A, et al. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells［J］. Life Sci,2016,153:41-49.
［17］Xie F, Liu J, Li C, et al. Simvastatin blocks TGF-β1-induced epithelial-mesenchymal transition in human prostate cancer cells［J］. Oncol Lett, 2016,11(5):3377-3383.
［18］Wolfe AR, Debeb BG, Lacerda, et al. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a［J］. Breast Cancer Res Treat,2015,154(3):495-508.
［19］Al-Haidari AA, Syk I, Thorlacius H. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation［J］. Biochem Biophys Res Commun,2014,446(1):68-72.
［20］Afshordel S, Kern B, Clasohm J, et al. Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation--impact of Ras-/Rho-prenylation［J］. Pharmacol Res,2015,91:69-77.
［21］Gan J, Li P, Wang Z, et al. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway［J］. Exp Ther Med,2013,6(4):899-903.
［22］Schointuch MN, Gilliam TP, Stine JE, et al. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer［J］. Gynecol Oncol,2014,134(2):346-355.
［23］Stine JE, Guo H, Sheng X, et al. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer［J］. Oncotarget,2016,7(1):946-960.
［24］Fang Z, Tang Y, Fang J,et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway［J］. PLoS One,2013,8(5):e62823.
［25］王红艳,龙捷,涂永生. 辛伐他汀抑制人非小细胞肺癌H460细胞迁移和MMP2的表达［J］. 中国临床药理学与治疗学,2015,20(7):732-735.
［26］Zhong S, Zhang X, Chen L, et al. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies［J］. Cancer Treat Rev,2015,41(6):554-567.
［27］Bansal D, Undela K, D'Cruz S, et al. Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies［J］. PLoS One,2012,7 (10): e46691.
［28］Raval AD, Thakker D, Negi H, et al. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis［J］. Prostate Cancer Prostatic Dis,2016,19(2):151-162.
［29］Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer［J］. J Clin Oncol,2014,32(1):5-11.
［30］Allott EH, Howard LE, Cooperberg MR, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database［J］. BJU Int,2014,114(5):661-666.
［31］Tan P, Wei S, Yang L, et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis［J］. Sci Rep, 2016,6:29106.
［32］van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition［J］. Gut, 2011,60(8):1094-1102.
［33］Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer［J］. N Engl J Med, 2005,352(21):2184-2192.
［34］Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population［J］. J Natl Cancer Inst,2008,100(2):134-139.
［35］Cai H, Zhang G, Wang Z,et al. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis［J］. PLoS One,2015,10(6):e0126944.
［36］Mamtani R, Lewis JD, Scott FI, et al. Disentangling the association between statins, cholesterol, and colorectal cancer: a nested case-control study［J］. PLoS Med,2016,13(4):e1002007.
［37］Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803［J］. J Natl Cancer Inst, 2011,103(20):1540-1551.
［38］Mace AG, Gantt GA, Skacel M, et al. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer［J］. Dis Colon Rectum,2013,56(11):1217-1227.
［39］Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies［J］. Breast Cancer Res Treat,2012,135(1):261-269.
［40］McDougall JA, Malone KE, Daling JR, et al. Long-term statin use and risk of ductal and lobular breast cancer among women 55-74 years of age［J］. Cancer Epidemiol Biomarkers Prev,2013,22:1529-1537.
［41］Mansourian M1, Haghjooy-Javanmard S, Eshraghi A, et al. Statins use and risk of breast cancer recurrence and death: a systematic review and meta-analysis of observational studies［J］. J Pharm Pharm Sci,2016,19(1):72-81.
［42］Nickels S, Vrieling A, Seibold P, et al. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort［J］. PLoS One,2013, 8 (9): e75088.
［43］Wu Q J, Tu C, Li YY, et al. Statin use and breast cancer survival and risk: a systematic review and meta-analysis［J］. Oncotarget,2015,6:42988-43004.
［44］Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis［J］. Ann Oncol,2013,24(7):1721-1730.
［45］Tan M, Song X, Zhang G, et al. Statins and the risk of lung cancer: a meta-analysis［J］. PLoS One,2013,8(2):e57349.
［46］Lin JJ, Ezer N, Sigel K,et al. The effect of statins on survival in patients with stage IV lung cancer［J］. Lung Cancer,2016,99:137-142.

[1]	范杰, 金永明, 江孝龙, 蒋国华. lncRNA HOTAIR调控miR-206影响类风湿关节炎滑膜细胞增殖和凋亡的分子机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 736-742.
[2]	李雅亭, 岳红梅, 刘苗苗, 许金回, 武兴东, 朱浩斌. 磷酸二酯酶4抑制剂作为特发性肺纤维化药物治疗的可能性[J]. 中国临床药理学与治疗学, 2023, 28(7): 818-823.
[3]	赵璐, 李付勇, 温滨红, 李道伟. 他汀类药物治疗伴高脂血症偏头痛患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2023, 28(6): 671-675.
[4]	杨晓佳, 江萌, 吴敏, 张伊黎, 吕兰, 吴嫄芬, 王鑫昱, 刘立权. 藏红花素介导DKK3调控GSK-3β/β-catenin通路对阿尔兹海默症大鼠的认知改善作用[J]. 中国临床药理学与治疗学, 2023, 28(5): 489-497.
[5]	侯小煜, 冷玉芳, 曹雪芬, 吕兴娇, 韩晓霞, Janvier NIBARUTA, 刘永强. 五味子乙素减轻小鼠肠缺血再灌注损伤的网络药理学分析及实验验证[J]. 中国临床药理学与治疗学, 2023, 28(2): 147-154.
[6]	王剑, 孙永东, 周兴玮, 刘雷, 陈龙, 童兴科, 朱佳丽. 黄芩素经由miR-125b-5p/IRF4轴进而促进喉癌细胞死亡并抑制其侵袭的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1209-1218.
[7]	朱瑞芳, 郭东凯, 智慧, 江翊国, 张悦翎, 钱晓萍, 季士亮. ROS-NF-κB-p38MAPK通路探索榄香烯联合硼替佐米抗多发性骨髓瘤的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1219-1226.
[8]	周欢, 徐铭, 李波, 刘春英, 王淳. PI3K/Akt/FOXO3a信号通路介导的保护性自噬参与肺腺癌获得性顺铂耐药表型重塑[J]. 中国临床药理学与治疗学, 2022, 27(9): 961-970.
[9]	王欣, 孙合亮, 张庆伟, 刘存明, 王忠云, 杨春. 小剂量艾司氯胺酮在胸腔镜下肺叶切除术患者术后镇痛中的作用[J]. 中国临床药理学与治疗学, 2022, 27(9): 998-1003.
[10]	华海燕, 严杰, 秦宇芬. 五味子乙素通过抑制心肌细胞凋亡减轻大鼠心肌缺血再灌注损伤的实验研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 848-856.
[11]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[12]	李雪恒, 李龙. 褪黑素与特发性肺纤维化关系的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(6): 715-720.
[13]	杨柳, 罗爱林, 李世勇. 全麻药物损伤发育期大脑的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1381-1390.
[14]	谭峰浪, 任宏丽, 王宏飞. 黄柏提取物对Aβ_1-42诱导的海马神经细胞的影响[J]. 中国临床药理学与治疗学, 2022, 27(11): 1213-1220.
[15]	潘蓉蓉, 支英豪, 金永喜, 周夏慧. 茶黄素调节CaMKK2/AMPK信号通路对脑出血大鼠神经元凋亡和血脑屏障的影响[J]. 中国临床药理学与治疗学, 2022, 27(11): 1240-1246.